News
May, 2025.
XEMPERIA featured in the Tages Anzeiger for developing a promising blood test for breast cancer early detection.
May, 2025.
Empowering Female Founders at the 141st SICTIC Investor Day at Google!
This event is designed to bring together investors and innovators committed to supporting the next generation of women-led companies. XEMPERIA is among the 9 Startups selected to present on stage.
> read more
https://www.sictic.ch/events/sid141/
May, 2025.
XEMPERIA was selected to pitch as the Swiss Start Up Day, Bern, May 14.
Startup days (SUD) are the nationwide business and networking platform for startups, investors, enablers, SMEs and corporates in Switzerland. XEMPERIA was among the 16 winners of among the 150+ newcomer start ups and was selected to pitch.
May, 2025.
Bilan publishes an article on XEMPERIA and its blood test for breast cancer screening.
The business magazine Bilan that targets managers of small or large enterprises and decision makers in Switzerland published an interview with Dr. Sarah Cattin and Prof. Curzio Rüegg. The article retraces the story of the project developed at the University of Fribourg that led to the text and the challenges ahead of XEMPERIA.
May, 2025.
XEMPERIA was selected in theTech4Eva accelerator program at EPFL, Lausanne.
Tech4Eva is a global Femtech community and a 6-month equity free Femtech start-up acceleration program for companies developing innovative women’s health solutions that create impact and change to improve women’s health – managed by non-profit Foundation EPFL Innovation Park. The program create impact in women’s health & accelerate global innovations
May, 2025.
XEMPERIA was selected to pitch as the Swiss Biotech Day, Basel, May 5-6.
The Swiss Biotech Day premier global biotechnology conference for life sciences professionals, fostering international collaboration and impactful partnerships. XEMPERIA was awarded the 3rd prize of the session Transformative Startups in Next-Gen Diagnostics
https://swissbiotechday.ch/
January, 2025.
XEMPERIA AG wins the second prize of the 2025 Ypsomed innovation award.
XEMPERIA is a spin-off project of the University of Fribourg and is setting new standards in the early detection and monitoring of cancer, with a focus on breast cancer. The company is developing technologies that combine state-of-the-art molecular diagnostics with powerful data analysis and AI-based pattern recognition.
October, 2024.
XEMPERIA AG wins the IFF First Prize for Start Up of the Canton Fribourg.
XEMPERIA is reinventing breast cancer screening with its blood test that test detects biomarkers in immune cells that have been altered by the presence of cancer cells. It offers a more accurate, affordable, and convenient method than mammography. Also it enables women under 50, who are often excluded from conventional methods, to access screening, making it more effective and widespread.
March, 2024
XEMPERIA was awarded a loan y the Foundation for Technological Innovation (FIT), Innovaud, Lausanne.
XEMPERIA was selected competitively among several Start-Ups to receive a Tech-Seed loan to start the preparation of a large scale validation study.
> read more
FIT-Innovaud-Actualité
January, 2023.
Press article in the journal “La Liberté” from West Switzerland.
This article introduces XEMPERIA and it leading breast cancer screenign project to the t local population.
December, 2023.
Incorporation of XEMPERIA SA.
XEMPERIA was founded as a Start Up and Spin-Off company of the University of Fribourg in Canton Fribourg on December 12, 2023, by Prof. Curzio Rüegg, Dr. Sarah Cattin and Atty. Tuto Rossi.
November, 2023.
Dr. Ivana Domljanovic finalist at international “Falling Wall” competition.
Dr. Ivana Domljanovic the Lab Fribourg winners of the prestigious “Falling Wall” pitch competition, with her “DNA origami diagnostic” project.
She was invited to compete with other international winners for the title of “Breakthrough Winner” at the international global finale pitch competition on the 7th of November in Berlin.
> read more
https://falling-walls.com/science-summit/
June, 2023.
Detecting breast cancer using a simple blood test.
Prof. Curzio Rüegg together with Yann Steulet, director of FriUp, discusson the radio Fribourg about this new innovative project. While traditionalmammography identifies tissues that are already affected, this new andless invasive method will make possible to detect the body’s immuneresponse to this disease, which affects nearly 6,000 patients inSwitzerland each year.
> read more
https://www.radiofr.ch/fribourg/podcasts/21483
June, 2023.
Dr. Ivana Domljanovic was awarded the prestigious Swiss Nanotechnology PhD Award 2023.
Prof. Curzio Rüegg received the Award for the Best Innovation Project at the Agora of the CHUV in Lausanne during the Bioinnovation Day. His team is developing a blood test for the early detection of breast cancer which could revolutionize the patients’ management and the disease treatment.
May, 2023.
Best Innovation Project Award at the 2023 Bioinnovation Day.
Prof. Curzio Rüegg received the Award for the Best Innovation Project at the Agora of the CHUV in Lausanne during the Bioinnovation Day. His team is developing a blood test for the early detection of breast cancer which could revolutionize the patients’ management and the disease treatment.
June, 2021.
Breast cancer: detecting the invisible.
Researchers at the University of Fribourg have shown that, even at an early stage, breast cancer causes an immune system reaction which can be detected by a blood test. This is an important result that opening new new prospects for breast cancer early detection.
- © 2025 Xemperia. All rights reserved | Imprint | Design: ZebraZbinden | Development: FRESCHI IT